Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has been given an average rating of “Buy” by the fifteen brokerages that are currently covering the firm, MarketBeat reports. Eight research analysts have rated the stock with a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $20.00.
Several equities research analysts have recently commented on the stock. BidaskClub cut shares of Sucampo Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. Zacks Investment Research cut shares of Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, February 9th. ValuEngine raised shares of Sucampo Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 2nd. Nomura reissued a “neutral” rating and set a $18.00 price target on shares of Sucampo Pharmaceuticals in a research report on Friday, January 26th. Finally, UBS Group cut shares of Sucampo Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $18.00 price target for the company. in a research report on Friday, January 5th.
Sucampo Pharmaceuticals (NASDAQ SCMP) remained flat at $$18.00 during trading hours on Wednesday. The stock had a trading volume of 303,068 shares, compared to its average volume of 2,770,000. Sucampo Pharmaceuticals has a 52 week low of $9.30 and a 52 week high of $18.75. The company has a debt-to-equity ratio of 7.37, a quick ratio of 4.46 and a current ratio of 5.11. The stock has a market capitalization of $839.46, a PE ratio of -5.37, a PEG ratio of 5.06 and a beta of 1.38.
Large investors have recently added to or reduced their stakes in the business. FDx Advisors Inc. bought a new stake in Sucampo Pharmaceuticals during the 4th quarter valued at about $180,000. Trexquant Investment LP bought a new stake in Sucampo Pharmaceuticals during the 3rd quarter valued at about $122,000. UBS Asset Management Americas Inc. bought a new stake in Sucampo Pharmaceuticals during the 4th quarter valued at about $192,000. Nine Chapters Capital Management LLC bought a new stake in Sucampo Pharmaceuticals during the 3rd quarter valued at about $127,000. Finally, JPMorgan Chase & Co. bought a new stake in Sucampo Pharmaceuticals during the 2nd quarter valued at about $117,000. Institutional investors and hedge funds own 67.09% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was posted by BBNS and is owned by of BBNS. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://baseballnewssource.com/markets/analysts-set-sucampo-pharmaceuticals-inc-scmp-target-price-at-20-00/1888804.html.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.